Skip to main content

Table 2 Therapeutic regimen

From: The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn’s disease in real world-data: a retrospective study

 

5-ASA

AZA

MTX

5-ASA + AZA

5-ASA + ABT

AZA + ABT

IFXa

ADAa

VEDOa

USTEa

COMBOa

SWITCH/SWAP

CCSb

Biological arm

–

–

–

–

–

–

15 (30.5%)

22 (45%)

4 (8%)

3 (6.5%)

5 (10%)

17 (35%)

49 (100%)

Conventional arm

8 (5%)

4 (2.5%)

4 (2.5%)

62 (40%)

38 (24.5%)

38 (24.5%)

–

–

–

–

–

–

154 (100%)

  1. 5-ASA Mesalamine, AZA Azathioprine, MTX Metrotexato, ABT Antibiotics Therapy, IFX Infliximab, ADA Adalimumab, VEDO Vedolizumab, USTE Ustekinumab, COMBO Combo therapy Infliximab and Azathioprine, CCS steroid; a: first therapeutic line b: at least one cycle
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us